Spots Global Cancer Trial Database for TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Official Title: Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octréoscan ® Scintigraphy and CT / MRI) in the Assessment of in Gastroenteropancreatic Neuroendocrine Tumors
Study ID: NCT01747096
Interventions
Study Description
Brief Summary: Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in routine clinical practice (octreoscan ® ; multiphase SPECT / CT, MRI or endoscopy). Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed. Expected results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy octreoscan ®, with a potential impact on the therapeutic management of patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Angers Hospital, Angers, , France
Hôpital Beaujon, Clichy, , France
Hôpital Bichat, Paris, , France
Institut de Cancérologie de l'Ouest, René Gauducheau, Saint Herblain, , France
Nantes Hospital, Saint Herblain, , France
Contact Details
Name: Catherine Ansquer, MD
Affiliation: Nantes Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
